CVS CVS HEALTH Corp
Retail-Drug Stores and Proprietary Stores · NYSE · SEC CIK 64803 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY6.7%
TTM net income YoY2,253.3%
TTM EPS YoY2,165.8%
Revenue 3-yr CAGR6.5%
Net income 3-yr CAGR8.5%
Margins
Gross margin44.2%
Operating margin3.6%
Net margin2.6%
FCF margin3.7%
EBITDA margin4.7%
Returns
ROE14.4%
ROA4.3%
ROIC (approx.)10.8%
Asset turnover1.64x
Leverage & solvency
Liabilities / assets68.7%
Debt / equity0.75x
Current ratio0.85x
Interest coverage4.91x
Cash quality & payout
Operating cash flow / net income1.70x
Accruals ratio-3.0%
Payout ratio31.0%
Capex / revenue0.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $402.07B | $372.81B |
| Cost of revenue | $221.17B | $206.29B |
| Gross profit | $180.90B | $166.52B |
| Operating income | $4.66B | $8.52B |
| Interest expense | $3.12B | $2.96B |
| Pretax income | $2.14B | $6.15B |
| Income tax | $408.00M | $1.56B |
| Net income | $1.77B | $4.61B |
| EBITDA | $9.27B | $13.11B |
| EPS (basic) | 1.40 | 3.67 |
| EPS (diluted) | 1.39 | 3.66 |
| Dividends declared per share | 2.66 | 2.66 |
| Weighted avg. shares (diluted) | 1.27B | 1.26B |
| Balance sheet | ||
| Cash & equivalents | $8.45B | $8.88B |
| Short-term investments | $2.15B | $2.41B |
| Receivables | $39.78B | $36.47B |
| Inventory | $19.25B | $18.11B |
| Current assets | $74.71B | $68.64B |
| PP&E, net | $13.08B | $12.99B |
| Goodwill | $85.48B | $91.27B |
| Intangibles | $25.51B | $27.32B |
| Total assets | $253.54B | $253.22B |
| Current liabilities | $88.69B | $84.61B |
| Short-term debt | $4.07B | $2.12B |
| Long-term debt | $60.50B | $60.53B |
| Total debt | $64.57B | $62.65B |
| Total liabilities | $178.16B | $177.49B |
| Shareholders' equity | $75.21B | $75.56B |
| Net debt | $56.12B | $53.76B |
| Shares outstanding | 1.27B | 1.26B |
| Cash flow statement | ||
| Operating cash flow | $10.64B | $9.11B |
| Capital expenditure | $2.83B | $2.78B |
| Free cash flow | $7.81B | $6.33B |
| Investing cash flow | -$5.87B | -$7.61B |
| Financing cash flow | -$4.94B | -$1.14B |
| Depreciation & amortization | $4.61B | $4.60B |
| Stock-based compensation | $535.00M | $540.00M |
| Dividends paid | $3.40B | $3.37B |
| Share buybacks | $0 | $3.02B |
Free plan shows the latest 2 periods; Pro shows all 19 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.